Search

A study conducted at Hebei Medical University in China explored the use of esmolol hydrochloride as an adjuvant therapy for new-onset atrial fibrillation (NOAF) in patients with severe sepsis. The study included 162 patients who were divided into a control group and an observation group. The results showed that the observation group, which received esmolol hydrochloride in combination with routine treatment, had improved cardiac function and reduced inflammation levels compared to the control group. The researchers concluded that esmolol hydrochloride has potential clinical value in treating patients with severe sepsis and NOAF. This research has been peer-reviewed. [Extracted from the article]